Literature DB >> 19355844

Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.

Annalena Venneri1, William J McGeown, Michael F Shanks.   

Abstract

Clinical trials of cholinesterase inhibitor (ChEI) drugs, although generally reporting only minimal improvements in patients with Alzheimer's disease (AD), indicate that a subgroup of patients may respond substantially to treatment. This study aimed to assess the clinically variable ChEI treatment effects in a group of patients with mild AD using a semantic association and an N-back light working memory activation paradigm. Twenty-six patients with probable mild AD treated with a ChEI for 20 weeks were retrospectively divided into responders and non-responders. Patients were classified as responders if their Clinician's Interview Based Impression of Change (CIBIC - Plus) score was four or less and if they had an increase of at least two points on the MMSE. These criteria resulted in two subgroups comprising nine responders and seventeen non responders. Nine healthy elderly age-matched controls were also recruited as a comparison group. ChEI treatment was accompanied by significant modulation of task induced activation increases in both fMRI tasks in AD responders. The effect of ChEI response was in effect a restoration of regional brain function in the same areas used by elderly controls when performing these tasks. In non-responders decrements in task related activation were observed and over time activation patterns appeared less like the elderly controls. Screening semantic fluency scores correlated negatively with activation increases at retest. In the paper, a tentative explanation is offered of why subgroups of patients with a similar clinical diagnosis and level of clinical severity show a different physiological response to ChE inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355844     DOI: 10.2174/156720509787602933

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  7 in total

Review 1.  Potential of functional MRI as a biomarker in early Alzheimer's disease.

Authors:  Reisa Sperling
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

Review 3.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 4.  Brain imaging in Alzheimer disease.

Authors:  Keith A Johnson; Nick C Fox; Reisa A Sperling; William E Klunk
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

5.  Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding.

Authors:  Shannon L Risacher; Yang Wang; Heather A Wishart; Laura A Rabin; Laura A Flashman; Brenna C McDonald; John D West; Robert B Santulli; Andrew J Saykin
Journal:  Front Psychiatry       Date:  2013-09-17       Impact factor: 4.157

6.  Retinal Structures and Visual Cortex Activity are Impaired Prior to Clinical Vision Loss in Glaucoma.

Authors:  Matthew C Murphy; Ian P Conner; Cindy Y Teng; Jesse D Lawrence; Zaid Safiullah; Bo Wang; Richard A Bilonick; Seong-Gi Kim; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

Review 7.  Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

Authors:  Elisa Canu; Elisabetta Sarasso; Massimo Filippi; Federica Agosta
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.